Renflexis (Infliximab-abda Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2018 Category: Drugs & Pharmacology Source Type: news
No Surgical Gains from Accelerated Infliximab in Acute UC
(MedPage Today) -- Colectomy rates similar to those with standard induction therapy (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 29, 2018 Category: Gastroenterology Source Type: news
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis
Amgen to Seek Regulatory Approvals
THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response difference meas...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Novartis touts effectiveness, safety of autoimmune drug copies
ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Novartis receives EU approval for biosimilar Zessly
ZURICH (Reuters) - Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. (Source: Reuters: Health)
Source: Reuters: Health - May 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar IBD Patients in Remission Can Safely Switch to Infliximab Biosimilar
Switching to CT-P13, an infliximab biosimilar, is safe and well tolerated in patients with IBD whose disease is in remission, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
EMA Committee Backs Remicade Biosimilar Zessly EMA Committee Backs Remicade Biosimilar Zessly
The committee favors marketing the infliximab biosimilar product Zessly for treatment of rheumatoid arthritis, Crohn ' s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2018 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Switching From Infliximab to Biosimilar in Patients With IBD Switching From Infliximab to Biosimilar in Patients With IBD
Two infliximab biosimilars are currently available for the treatment of inflammatory bowel disease, at a much lower cost than infliximab innovator. Can patients be safely switched?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn's Disease Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn's Disease
Symptoms alone are as useful as a combination of symptoms, biomarkers and serum drug concentrations for determining the need for an increased dose of infliximab in patients with Crohn ' s disease (CD), according to results from a randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 29, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
U.S. Appeals Court Invalidates J & J Patent on Remicade U.S. Appeals Court Invalidates J & J Patent on Remicade
A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson& Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J ’ s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
U.S. appeals court upholds ruling invalidating J & J patent on Remicade
(Reuters) - A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson& Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J ’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. (Source: Reuters: Health)
Source: Reuters: Health - January 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Biosimilars, Biologics, New Legal Challenges for RA Treatments Biosimilars, Biologics, New Legal Challenges for RA Treatments
Early last winter, Pfizer launched its new rheumatoid arthritis treatment, Inflectra, pricing it 15 percent below the $4,000-a-dose wholesale price of Remicade, the drug for which it is a close copy.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 29, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news
FDA approves new Pfizer biosimilar
Pfizer Inc. (NYSE:PFE) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product. (Source: World Pharma News)
Source: World Pharma News - December 15, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
FDA Clears Another Remicade Biosimilar (Ixifi) FDA Clears Another Remicade Biosimilar (Ixifi)
The FDA has approved Pfizer ' s infliximab-qbtx (Ixifi) for all eligible indications for the US-licensed reference product.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news
Pfizer's second biosimilar of J & J's Remicade wins U.S. FDA approval
(Reuters) - The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson& Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - December 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
